Travere Therapeutics (TVTX) Other Operating Expenses (2011 - 2026)
Travere Therapeutics posted quarterly Other Operating Expenses of $26.8 million for Q1 2026, up 56.49% year-on-year from $17.1 million in Q1 2025, and up 948.41% on a QoQ basis from $2.6 million in Q4 2025.
Travere Therapeutics (TVTX) has 16 years of Other Operating Expenses data on file, last reported at $26.8 million in Q1 2026.
- For the quarter ending Q1 2026, Other Operating Expenses rose 56.49% year-over-year to $26.8 million; the trailing twelve-month figure through Mar 2026 stood at $32.4 million (up 38.68% YoY), and the FY2025 full-year result was $10.3 million, down 85.83% from the prior year.
- Other Operating Expenses for Q1 2026 stood at $26.8 million, up from $2.6 million in the prior quarter.
- Across five years, Other Operating Expenses topped out at $66.7 million in Q1 2024 and bottomed at -$8.0 million in Q1 2022.
- The 5-year median for Other Operating Expenses is $1.6 million (2024), against an average of $7.2 million.
- The widest annual swing landed in 2022, when Other Operating Expenses sank 274.05%; it then jumped 1509.38% in 2024.
- A 5-year view of Other Operating Expenses shows it stood at $868000.0 in 2022, then soared by 425.81% to $4.6 million in 2023, then tumbled by 43.23% to $2.6 million in 2024, then decreased by 1.47% to $2.6 million in 2025, then soared by 948.41% to $26.8 million in 2026.
- The last three Other Operating Expenses figures came in at $26.8 million (Q1 2026), $2.6 million (Q4 2025), and $1.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Travere Therapeutics | 4.34 Bn | 4.26 Bn | 102.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 26.77 Mn |
| Dec 31, 2025 | 2.55 Mn |
| Sep 30, 2025 | 1.59 Mn |
| Jun 30, 2025 | 1.52 Mn |
| Mar 31, 2025 | 17.10 Mn |
| Dec 31, 2024 | 2.59 Mn |
| Sep 30, 2024 | 1.63 Mn |
| Jun 30, 2024 | 2.06 Mn |
| Mar 31, 2024 | 66.71 Mn |
| Dec 31, 2023 | 4.56 Mn |
| Sep 30, 2023 | 1.29 Mn |
| Jun 30, 2023 | 1.45 Mn |
| Mar 31, 2023 | 4.15 Mn |
| Dec 31, 2022 | 868,000.00 |
| Sep 30, 2022 | 1.11 Mn |
| Jun 30, 2022 | -5.50 Mn |
| Mar 31, 2022 | -8.01 Mn |
| Dec 31, 2021 | -25.03 Mn |
| Sep 30, 2021 | 15.46 Mn |
| Jun 30, 2021 | 3.16 Mn |
| Mar 31, 2021 | 10.23 Mn |
| Dec 31, 2020 | 95.41 Mn |
| Sep 30, 2020 | 6.27 Mn |
| Jun 30, 2020 | 5.78 Mn |
| Mar 31, 2020 | -552,000.00 |
| Dec 31, 2019 | 10.96 Mn |
| Sep 30, 2019 | 15.81 Mn |
| Jun 30, 2019 | 4.33 Mn |
| Mar 31, 2019 | 11.69 Mn |
| Dec 31, 2018 | -9.44 Mn |
| Sep 30, 2018 | 17.73 Mn |
| Jun 30, 2018 | 3.34 Mn |
| Mar 31, 2018 | 5.24 Mn |
| Dec 31, 2017 | 9.52 Mn |
| Sep 30, 2017 | 6.49 Mn |
| Jun 30, 2017 | 3.10 Mn |
| Mar 31, 2017 | 3.56 Mn |
| Mar 31, 2016 | 3.45 Mn |
| Dec 31, 2015 | -124.50 Mn |
| Sep 30, 2015 | 140.00 Mn |
| Jun 30, 2015 | 15.50 Mn |
| Mar 31, 2015 | 204,198.00 |
| Jun 30, 2014 | 35,000.00 |
| Mar 31, 2014 | 1,331.00 |
| Dec 31, 2013 | 230,014.00 |
| Sep 30, 2013 | 875,986.00 |
| Jun 30, 2013 | 489,902.00 |
| Mar 31, 2013 | -255,516.00 |
| Nov 30, 2012 | 500.00 |
| Aug 31, 2012 | 500.00 |
| May 31, 2012 | 500.00 |
| Nov 30, 2011 | 500.00 |
| Aug 31, 2011 | 500.00 |
| Feb 28, 2011 | 500.00 |